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235 U (108)/200 U (100-440) was injected. Based on a BoNT-A injection interval of 12 
weeks, the annual cost per patient in the UK would be 1,068 GBP for abobotulinum-
toxinA, 1,198 GBP for onabotulinumtoxinA and 1,399 GBP for incobotulinumtox-
inA. ConClusions: Considering the real life practice of BoNT-A injections and the 
comparison of treatment groups treated for the same limb segment, this analysis 
suggests that the use of abobotulinumtoxinA would result potentially in a reduction 
in the health care cost for the treatment of spasticity and that more patients could 
be treated with abobotulinumtoxinA with a given budget.
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objeCtives: The objective is to compare the hospitalization length of stay and 
costs associated with comorbidities between dialysis patients and non-dialysis 
patients. Methods: This was a cross-sectional observational study (from January 
to December 2010) of a national hospitalization database from the Brazilian Unified 
Public Healthcare System (Sistema Único de Saúde – SUS). Patients included in 
the study were hospitalized due to 3 predefined comorbidities categories: heart 
disease, vascular disease, and osteometabolic diseases, identified using ICD-10 
codes. Results: A total of 491,644 admissions were observed in patients not on 
dialysis (control group), while 2,627 admissions were identified in dialysis patients. 
The comparative analysis of causes of hospitalization showed that a larger propor-
tion of admissions due to heart disease was observed in patients on dialysis (61%) 
compared to the control group (47.9%), the opposite was observed for vascular and 
osteometabolic hospitalizations. For all 3 categories, cost of hospitalization for dialysis 
patients is at least two-fold higher and the length of stay almost 3 times longer (21 
days for dialysis patients versus 8 days for non-dialysis) than non-dialysis patients. 
The greatest differences between these two patient populations are in average costs 
among dialysis patients hospitalized for osteometabolic disorders versus control 
group and the highest burden regarding length of hospital stay, due to heart dis-
ease. ConClusions: There is a high hospitalization burden among CKD-5D patients 
in the Brazil health care system. Since inpatient costs were the key cost drivers for 
CKD, strategies that reduce the risk of hospitalization and increase prevention of 
comorbidities may substantially decrease the overall health care economic burden.
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objeCtives: Ankle sprains and fractures are common injuries affecting many 
individuals, often requiring substantial and costly medical interventions. Ankle 
injuries can have significant physical and economic consequences. Therefore, the 
objectives of this study were to systematically review and describe the literature 
on the direct and indirect costs related to the diagnosis and treatment of ankle 
sprains and fractures. Methods: A systematic literature review of Ovid MEDLINE, 
EMBASE, Cochrane DSR, ACP Journal Club, AMED, Ovid Healthstar, and CINAHL was 
conducted for English-language studies on ankle sprains and fractures published 
from January 1980 to December 2013. Two reviewers assessed the articles for study 
quality using available giudelines and abstracted the data. Results: Overall, 1,415 
studies were identified of which 16 were selected for analysis. A majority of the 
studies were published in the last decade. The costs of ankle sprain diagnosis and 
management ranged from $495 to $4,667 per patient (2014 USD). The costs of stable 
ankle fracture diagnosis and management ranged from $89 to $602 per patient. 
However, the management costs were higher for unstable ankle fractures ($2,680 
to $15,095) and open fractures and varied depending on the severity of injury. The 
economic evaluations were conducted from the societal or health care system per-
spective. ConClusions: The costs of diagnosing and treating ankle sprains and 
fractures varied among the studies mostly due to differences in injury severity 
and the study characteristics. Future studies undertaking economic evaluations 
should follow the available guidelines and ensure that their methods are transpar-
ent and understandable especially the study perspective and the valuation of the 
costs and outcomes.
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objeCtives: The aim of the study is to estimate the pension costs (social secu-
rity system in Italy is financed by public expenditure) induced by patients with 
musculoskeletal disorders (MD) and specifically for rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Italy, between 2009 and 
2012. Methods: We analysed the database of National Institute of Social Security 
(INPS) to estimate for MD, RA, AS and PsA, the total costs of for three types of 
social security benefits: disability benefits (for people with reduced work ability), 
disability pensions (for people who are not eligible to be considered as workers) 
and incapacity pensions (for people without work ability). Also was estimated the 
productivity loss for RA in the 2013 with data from the National Institute of Statistics 
and from national literature review. Results: From 2009 to 2012 were paid about 
320 thousand benefits at a cost of approximately € 1.7 billion, for an average of just 
over 80,000 performances a year with a cost of € 432 million per year. Specifically 
the total pension burden for RA was about € 99 million, for AS was € 26 million and 
for PsA was € 12 million. The loss of productivity for AR in 2013 amounted to € 
707,425,191 due to 162,360 workers with RA that determine 9,174,221 working days 
ages because of the disease’s symptoms and variability, leading to reduced social 
engagement. *exchange rate: 303,59HUF/EUR
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objeCtives: Rheumatic diseases (RD) cause physical disability that may lead to 
early retirement, generating high indirect costs to society. We estimate these costs 
in the Portuguese population approaching the statutory retirement age. Methods: 
Health, sociodemographic and occupational data was retrieved from the 4th 
National Health Survey (2005/2006), for all people between 50 and 64 years of age 
(3,762 men and 4,241 women), whilst an official wage national database was used 
to estimate productivity values by gender, age-group and region, using the human 
capital approach. The effects of RD on the likelihood of early retirement and the 
attributable fractions estimates were obtained at the individual level by logistic 
regression. Results: At the time of the survey, 37.2% of the population with ages 
50-64 years old self-reported at least one RD and among these 22.7% were officially 
retired, compared with 17.6% of those without RD (p< 0.001). Females had higher 
prevalence of RD (49.8% vs. 23.4% for males; p< 0.001). Presence of RD was associated 
with early retirement regardless of age, gender and region (OR= 1.3; CI 95%: 1.0 - 1.6). 
The estimated annual indirect costs following premature retirement attributable 
to RD were € 367 million (€ 504 per RD patient). Age-groups closer to the statutory 
retirement age contribute more to the overall indirect costs and also have higher 
individual productivity values. For instance, 60-64 years old age-group contribute 
with 52% of overall costs and had an average indirect cost of 699€ per RD patient. 
Females were responsible for about 55% of these costs, however males contrib-
ute with higher individual productivity losses (cost per patient: 788€ vs. 390€ , for 
males and females respectively). ConClusions: Annual early retirement indirect 
costs attributable to RD are considerable. These results highlight the need to target 
patients with rheumatic conditions in order to obtain health and productivity gains 
and reduce early retirement in society.
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objeCtives: Psoriatic arthritis (PsA) entails an individual burden to patients and 
ties up resources. This study aimed to assess the total costs of PsA, including the 
indirect burden of PsA patients in Hungary and to obtain an overview of patients’ 
status, demographics, morbidity, and working capacity. Methods: Between 
January–March 2014, a questionnaire survey was conducted among PsA patients 
and filled out voluntarily and anonymously. Missing data was not imputed in the 
analysis; considered patient number is presented next to results if lower than total 
patient number. Results: 145 patients completed the questionnaire, of which 57% 
were women. Mean age was 54 years (Standard Deviation [SD]: 14 years) and aver-
age disease duration was 17 years (SD: 11 years). At primary diagnosis of PsA, 79% 
of patients had a full-time job, 4% a part-time job and only 3% received disability 
pension. At time of survey, only 32% of patients worked full-time, 4% part-time, and 
the proportion of disability pensioners increased to 28%. Cost calculation results* 
showed that the average annual total cost per PsA patient was 3,842€ . Within this, 
average annual direct non-medical cost was approximately 1,318€ (141 patients) and 
average annual indirect cost per patient was approximately 2,635€ (142 patients). 
Wage loss due to disability pension generated the highest average annual indirect 
cost per patient (2,734€ – 119 patients). In the working-age population (95 patients, 
31–62 years) total average cost per patient was 5,334€ . ConClusions: PsA can 
cause patients to become partially or completely disabled, which imposes a signifi-
cant burden directly on their environment and indirectly to society. Average direct/
indirect costs are higher with longer disease duration and greater skin manifesta-
tions. Patients may already be driven out from the labour market in their active 
ages because of the disease’s symptoms and variability, leading to reduced social 
engagement. *exchange rate: 303,59HUF/EUR
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objeCtives: To evaluate the real life practice of the use of botulinum toxin A 
(BoNT-A) in post-stroke upper limb spasticity and the economic consequences of 
fair comparisons of the dosing between either abobotulinumtoxinA (Dysport®) or 
onabotulinumtoxinA (Botox®) or incobotulinumtoxinA (Xeomin®). Methods: 
ULIS-II is an observational, prospective study, conducted in 84 centers in 22 coun-
tries. Of 456 adults with post-stroke upper limb spasticity presenting for treatment 
with BoNT-A, 193 patients with the same injected limb segments “upper arm and 
lower arm” were analyzed for the dose injected for one cycle of BoNT-A. Treatment 
and concomitant interventions were in accordance with routine local clinical prac-
tice. Sample size, mean (SD)/median dose (min-max) in Unit for each BoNT-A and 
annual cost per patient were calculated using the mean dose administered and 
considering no vial sharing. An injection interval of 12 weeks was simulated for 
all BoNT-A treatments and the UK listed public price was used to ascertain annual 
cost. Results: For the abobotulinumtoxinA group (N= 141) a mean (SD)/median 
(min-max) dose of 665 U (280)/500 U (150-1500) was injected, for the onabotuli-
numtoxinA group (N= 37) a mean (SD)/median dose of 183 U (99)/200 U (50-500) 
was injected and for incobotulinumtoxinA (N= 15), a mean (SD)/median dose of 
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3.83% prevalence. The 20 most frequent treatments accounts for 82.12 % (1016057) of 
total services. The following top-10 medical procedure were responsible for 58,05% 
(718.276) of total activities: 1) Ultrasound therapy 118806 (9.60%), 2) Iontophoresis 
100788 (8.15%), 3) Passive movement 80424 (6.50%), 4) Mid-frequency treatment 
77434 (6.26%), 5) Muscle strengthening exercises 62049 (5.02%), 6) Hand Massage 
62026 (5.01%), 7) Ergo therapy 60462 (4.89%), 8) Spinal Mobilization 57609 (4.66%), 
9) Diadynamic interference management 54092 (4.37%), 10) Training for circula-
tion improvement 44586 (3.60%). Physiotherapy out-patient care for Low Back Pain 
patients were 1.23 million cases with 294 million Hungarian Forint (0.96 million 
Euro) health insurance subsidy. ConClusions: The list of the 20 most frequent 
types of services reflects to the demand for the combination of active and passive 
exercises in Hungary. In case of capacity planning for diagnostic and therapeutic 
procedures, these findings should be considered.
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objeCtives: The number of hip fracture hospitalizations in the U. S. was approxi-
mately 352,000 in 2011 and expected to rise. The consequences of hip fractures are 
significant regarding the associated negative impacts on functioning and quality of 
life. Intertrochanteric hip fractures are frequently stabilized surgically using cepha-
lomedullary nails (CM). Complications may include post-operative femoral-shaft 
fracture, mechanical complications, and delayed/non-union, requiring reoperations 
that increase risk to the patient and cost to the health care system. Methods: A 
retrospective analysis of the Premier research database was conducted. Patients 
diagnosed with open and/or closed intertrochanteric fractures (ICD-9-CM codes 
820.2x or 820.3x) and treated for Hip Fracture (MS-DRG 480-482) from 1-JAN-2008 
through 30-JUN-2012 were included in the study. Among this population, patients 
treated with IM were identified using standard charge descriptions within orthope-
dic-implant hardware charges. To identify patients who had a reoperation, patient-
level admission records starting from index admission up to 12-months post-index 
procedure were investigated within the same MS-DRG classifications. Results: 
Overall, 73,745 patients qualified for the study (71% female; 74% ≥ 75-years-old). 
Of these, 32,175 (44%) were treated using CM. The average hospital cost of the 
index procedure was $15,798USD per patient (inclusive of fixed and variable costs), 
of which the average cost of the orthopedic nails was $1,704USD. Among these 
patients, a total of 419 (1.3%) patients were readmitted at 427 occasions within the 
12-month study period. The mean hospital cost of treating these readmissions was 
$16,352USD, and the primary diagnoses codes for these readmissions included fem-
oral fractures, nonunions, and device/mechanical complications. ConClusions: 
Although the incidence of readmission following a hip fracture is low, the eco-
nomic burden placed on the health care system and the humanistic burden are 
both significant. The incidence rate and long-term sequelae for hip fractures are 
well documented in the literature; however, the mean costs to a hospital have not 
yet been published.
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objeCtives: The Hungarian health budget does not allow all candidates to be 
promptly operated on with vertebral malformation. The budget is enough for 
approximately 4000 stabilizations by implant. The rest have to be put on the wait-
ing list. The aim of our study is to analyse the costs related to the patients being on 
waiting list for surgery of vertebral malformation. Methods: Data derived from 
the nationwide financial database of the Hungarian National Health Insurance Fund 
Administration. 71 patients on waiting list of an institute in 2005-2006 were studied. 
We analysed the average waiting time and the costs related to patients either oper-
ated on or without operation. Results: The average age of all candidates was 55 
year and the average waiting time was 32 months. The treatment cost during the 
waiting time was US$ 103 per month per patient. The average age of candidates 
operated on was 57 years and their average waiting time was 15 months with a costs 
of US$ 155 per month per patients. The average age of candidates not operated on 
was 54 years and their average waiting time was 15 months with a cost of US$ 92 
per month per patient. ConClusions: Half of candidates have not been operated 
on, because at the appointed date they postponed the operation. But they seem not 
to really want to be operated on. The reason could be they were not sure enough to 
be able to get job after the operation at their age.
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objeCtives: Target measures such as DAS-28 < 2.6 are the goal of treatment in 
rheumatoid arthritis (RA). In general, DAS-28< 2.6 is associated with improved func-
tionality and reduced resource use but with higher treatment costs. This study 
evaluated whether treatment strategies that were more effective but more expen-
sive in achieving DAS-28< 2.6 in moderate to severe RA patients were cost effective 
(CE). Methods: A micro-simulation model of 10,000 RA patients was developed 
that estimated lifetime Health Assessment Questionnaire (HAQ) progression, quality 
adjusted life years (QALYs) and direct costs from a UK NHS perspective. The model 
incorporated an initial response criterion of achieving a DAS-28 < 2.6 at 6 months 
lost. ConClusions: The most important indirect costs in Italy from 2009 to 2012 
was represented by disability benefits (69% of the total indirect cost), followed by 
disability pensions (28% of cost) and incapacity pensions (3% of cost). A better pre-
scription appropriateness and rapid access to innovative treatments (Italy, among 
the EU Countries, is the one with the greatest delay in access) would reduce the 
costs incurred by the social security system accompanied by an improvement on 
the effectiveness of interventions.
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objeCtives: Societal cost evidence relating to patients with psoriatic arthritis (PsA) 
is required to understand the overall economic impact of the disease. The objective 
of this research was to systematically review the published data relating to the soci-
etal burden of PsA. Methods: Embase, Medline, and Cochrane databases (accessed 
November 2013) were interrogated. Studies reporting on non-health sector costs or 
work disability associated with PsA were eligible for inclusion with no geographical 
restriction. Results: In total, 19 studies met eligibility criteria of the review; nine 
studies reported indirect costs associated with PsA and 11 studies reported PsA-
related work disability. Studies were conducted across Europe, USA, Canada, and 
Asia. Methodology used to calculate indirect cost estimates differed among studies; 
seven studies defined indirect costs as costs associated with productivity loss only, 
and two studies adopted a wider definition whereby indirect costs included produc-
tivity loss and out-of-pocket costs expenses (e. g. transportation, informal care, and 
home aids). Annual indirect cost associated with PsA, calculated using the human 
capital or friction capital approach, ranged from € 1,261 (Spain) to € 7,919 (Germany), 
with the majority of studies (71%) reporting annual indirect costs of less than € 4,000 
per person. Considerable heterogeneity was reported, with indirect costs of € 74,009 
over a two year period estimated in Norway, compared with 6-month costs of € 576 
in Italy. Indirect costs accounted for between 38% and 72% of total costs. Work 
disability estimates ranged from 5% to 39%. Disease severity, age, and gender were 
reported as main drivers of indirect costs and work disability. ConClusions: Cost 
associated with productivity loss represented the majority of indirect costs associ-
ated with PsA. Comparison of studies is confounded by heterogeneity between 
studies. Further research into the societal costs associated with patients with PsA 
in the UK is required as no studies reporting UK specific costs were identified.
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objeCtives: Ankylosing spondylitis (AS), one of the most common spondyloarth-
ritides, is a chronic condition with a significant impact on patient quality of life 
(QoL), particularly physical functioning. The objective of this research was to sys-
tematically review published data relating to the societal burden of AS. Methods: 
Embase, Medline, and Cochrane databases (accessed November 2013) were interro-
gated. Studies reporting on non-health sector costs or work disability associated with 
AS were eligible for inclusion. Results: In total, 42 studies met eligibility criteria; 19 
studies reported indirect costs associated with AS and 23 studies reported AS-related 
work disability. Studies were conducted across Europe, Africa, North America, and 
Asia. All studies defined indirect costs as costs associated with productivity loss. 
Annual indirect costs, calculated using the human capital approach, ranged from € 595 
(Belgium) to € 9,837 (Germany). Friction costs calculated ranged from € 428 (France) to 
€ 6,843 (Spain). Considerable heterogeneity was reported, with 2-year indirect costs 
of € 66,907 estimated in Norway. Despite heterogeneity between studies, 75% of pub-
lications reported indirect costs of less than € 4,500 per patient/year, representing 
between 34% and 74% of total costs. Non-medical costs such as informal care, and 
transportation ranged from $65 (US) to $3,663 (US), indicating that loss of productivity 
was the main driver of indirect costs. Estimates of work disability varied greatly across 
studies primarily due to heterogeneous populations and the lack of standardised 
questionnaires. The work disability of AS was multifactorial with regression analyses 
identifying several factors associated with both indirect costs and disability includ-
ing demographic factors, disease and job characteristics. ConClusions: Although 
reported indirect costs and work disability estimates varied between studies, findings 
from this systematic review indicate that AS represents a substantial burden both on 
society and individuals with AS. A lack of UK-based data illustrates the challenge of 
incorporating societal costs into future UK reimbursement submissions.
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objeCtives: The aim of our study is to assess amount and frequency of the physi-
otherapy services in Low Back Pain disease and determine the total health insurance 
reimbursement. Methods: Data were derived from the countrywide database of 
Hungarian Health Insurance Administration (HHIA), based on official reports of 
outpatient care institutes in 2009. The total numbers of different physiotherapy 
services were determined by selecting the reported specific diagnoses codes and 
counting the number treatments provided for that specific diagnosis code. The dif-
ferent types of treatment codes are listed in the chapter of the Guidelines of HHIA 
for `Physiotherapists, massage-therapists, conductors and other physiotherapy 
practices`. The Low Back Pain was reported according to WHO ICD diagnosis code 
M5450. Results: Low Back Pain account for 1237263 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approximately 
